Press Releases

Date Title and Summary Additional Formats
Toggle Summary Amphastar Announces Approval for Glucagon for Injection Kit, 1mg
RANCHO CUCAMONGA, Calif. , Dec. 29, 2020 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. , (NASDAQ: AMPH) announced that the U.S. Food and Drug Administration (“FDA”) has approved its Abbreviated New Drug Application (“ANDA”) for Glucagon for Injection Emergency Kit, 1 mg.
View HTML
Toggle Summary Amphastar Announces Approval for Glucagon for Injection Kit, 1mg
RANCHO CUCAMONGA, Calif., Dec. 29, 2020 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc., (NASDAQ: AMPH) announced that the U.S. Food and Drug Administration (“FDA”) has approved its Abbreviated New Drug Application (“ANDA”) for Glucagon for Injection Emergency Kit, 1 mg.
View HTML
Toggle Summary Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended September 30, 2020
Reports Net Revenues of $83.4 Million for the Three Months Ended September 30, 2020 RANCHO CUCAMONGA, Calif. , Nov. 06, 2020 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) (“Amphastar” or the “Company”) today reported results for the three months ended September 30, 2020 .
View HTML
Toggle Summary Amphastar Pharmaceuticals to Release Third Quarter Earnings and Hold Conference Call on November 6th, 2020
RANCHO CUCAMONGA, Calif. , Oct. 29, 2020 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) announced that the Company will release results for its third quarter of 2020 ended September 30, 2020 , before the market opens on Friday, November 6 th , 2020, and will hold a conference
View HTML
Toggle Summary Amphastar Pharmaceuticals Receives FDA Approval for Atropine Sulfate Injection
RANCHO CUCAMONGA, Calif. , Oct. 06, 2020 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) announced that the U.S. Food and Drug Administration (“FDA”) approved the Company’s Abbreviated New Drug Application (“ANDA”) for Atropine Sulfate injection 0.1mg/mL in the 10 mL Luer-Jet ®
View HTML
Toggle Summary Amphastar Pharmaceuticals to Present at the Wells Fargo 2020 Virtual Healthcare Conference
RANCHO CUCAMONGA, Calif. , Sept. 03, 2020 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) announced today that Bill Peters , CFO, Dan Dischner , Vice President of Corporate Communications and Human Resources, and Tony Marrs , Sr. Vice President Regulatory Affairs and Clinical
View HTML
Toggle Summary Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended June 30, 2020
Reports Net Revenues of $85.8 Million for the Three Months Ended June 30, 2020 RANCHO CUCAMONGA, Calif. , Aug. 06, 2020 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) (“Amphastar” or the “Company”) today reported results for the three months ended June 30, 2020 .
View HTML
Toggle Summary Amphastar Pharmaceuticals to Release Second Quarter Earnings and Hold Conference Call on August 6th, 2020
RANCHO CUCAMONGA, Calif. , July 30, 2020 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) announced that the Company will release results for its second quarter of 2020 ended June 30, 2020 , after the market closes on Thursday, August 6th, 2020 , and will hold a conference call to
View HTML
Toggle Summary Amphastar Pharmaceuticals to Present at the BMO Prescriptions for Success Healthcare Conference
RANCHO CUCAMONGA, Calif. , June 19, 2020 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) announced today that Bill Peters , CFO, Dan Dischner , Vice President of Corporate Communications and Human Resources, and Tony Marrs , Sr. Vice President Regulatory Affairs and Clinical
View HTML
Toggle Summary Amphastar Pharmaceuticals to Present at the Raymond James Virtual 2020 Human Healthcare Innovation Conference
RANCHO CUCAMONGA, Calif. , June 12, 2020 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) announced today that Bill Peters , CFO, Dan Dischner , Vice President of Corporate Communications and Human Resources, and Tony Marrs , Sr. Vice President Regulatory Affairs and Clinical
View HTML

 

Copyright ©2021 Amphastar Pharmaceuticals, Inc.

Privacy      Terms & Conditions

This site is intended for residents of the United States